pioglitazone and Cirrhosis, Liver studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research Excerpts

Excerpt	Relevance	Reference
" Coadministration of pioglitazone with peginterferon/ribavirin improves insulin sensitivity and increases virologic response rates in insulin-resistant HCV genotype 4 patients, but it is unclear whether this finding applies to genotype 1 patients."	9.16	Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. ( Hamzeh, FM; Han, J; Harrison, SA; Pandya, PK; Sheikh, MY; Vierling, JM, 2012)
"We randomly assigned 55 patients with impaired glucose tolerance or type 2 diabetes and liver biopsy-confirmed nonalcoholic steatohepatitis to 6 months of treatment with a hypocaloric diet (a reduction of 500 kcal per day in relation to the calculated daily intake required to maintain body weight) plus pioglitazone (45 mg daily) or a hypocaloric diet plus placebo."	9.12	A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. ( Balas, B; Bannayan, GA; Belfort, R; Berria, R; Brown, K; Cusi, K; Darland, C; DeFronzo, R; Dwivedi, S; Finch, J; Fincke, C; Gastaldelli, A; Hardies, J; Harrison, SA; Havranek, R; Ma, JZ; Pulcini, J; Schenker, S; Tio, F, 2006)
" Pioglitazone, vitamin E, a weight reduction program, and usual care were investigated, with the outcomes of interest being the number of cirrhosis and hepatocellular carcinoma (HCC) cases, life expectancy, quality-adjusted life-years (QALYs), lifetime costs, and the incremental cost-effectiveness ratios (ICERs)."	7.91	Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand. ( Chaiyakunapruk, N; Chongmelaxme, B; Dilokthornsakul, P; Phisalprapa, P; Sawangjit, R, 2019)
"Chronic treatment with pioglitazone exerts a more prominent gastroprotective effect on the stomach ulcers of cirrhotic rats compared to control group probably due to constitutive nitric oxide synthase induction or inducible nitric oxide synthase inhibition."	7.79	Enhanced anti-ulcer effect of pioglitazone on gastric ulcers in cirrhotic rats: the role of nitric oxide and IL-1β. ( Amirghofran, Z; Dehpour, AR; Heidari, R; Moezi, L; Monabati, A; Nekooeian, AA, 2013)
" Liraglutide leading to improve not only glycaemic control but also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients."	7.78	The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. ( Isogawa, A; Iwamoto, M; Koike, K; Ohki, T; Ohsugi, M; Omata, M; Tagawa, K; Toda, N; Yoshida, H, 2012)
"Pioglitazone is an effective agent for chemoprevention in rodents and could be repurposed as a multi-targeted drug for delaying liver fibrosis and hepatocarcinogenesis."	5.51	Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. ( Arora, G; Baumert, TF; Erstad, DJ; Fuchs, BC; Ghoshal, S; Hoshida, Y; Lanuti, M; Li, S; Masia, R; Sojoodi, M; Tanabe, KK, 2019)
" Coadministration of pioglitazone with peginterferon/ribavirin improves insulin sensitivity and increases virologic response rates in insulin-resistant HCV genotype 4 patients, but it is unclear whether this finding applies to genotype 1 patients."	5.16	Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. ( Hamzeh, FM; Han, J; Harrison, SA; Pandya, PK; Sheikh, MY; Vierling, JM, 2012)
"We randomly assigned 55 patients with impaired glucose tolerance or type 2 diabetes and liver biopsy-confirmed nonalcoholic steatohepatitis to 6 months of treatment with a hypocaloric diet (a reduction of 500 kcal per day in relation to the calculated daily intake required to maintain body weight) plus pioglitazone (45 mg daily) or a hypocaloric diet plus placebo."	5.12	A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. ( Balas, B; Bannayan, GA; Belfort, R; Berria, R; Brown, K; Cusi, K; Darland, C; DeFronzo, R; Dwivedi, S; Finch, J; Fincke, C; Gastaldelli, A; Hardies, J; Harrison, SA; Havranek, R; Ma, JZ; Pulcini, J; Schenker, S; Tio, F, 2006)
" Pioglitazone, vitamin E, a weight reduction program, and usual care were investigated, with the outcomes of interest being the number of cirrhosis and hepatocellular carcinoma (HCC) cases, life expectancy, quality-adjusted life-years (QALYs), lifetime costs, and the incremental cost-effectiveness ratios (ICERs)."	3.91	Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand. ( Chaiyakunapruk, N; Chongmelaxme, B; Dilokthornsakul, P; Phisalprapa, P; Sawangjit, R, 2019)
" The aim of the present study was to elucidate the role of the TLR4‑dependent signaling pathway, and examine the effect of pioglitazone on hepatic fibrosis, through modulation of the TLR4 pathway in a mouse model of nutritional fibrotic steatohepatitis."	3.83	TLR4‑dependent signaling pathway modulation: A novel mechanism by which pioglitazone protects against nutritional fibrotic steatohepatitis in mice. ( Du, J; Kong, L; Nan, Y; Niu, X; Wang, R; Zhang, Y; Zhao, S, 2016)
"Chronic treatment with pioglitazone exerts a more prominent gastroprotective effect on the stomach ulcers of cirrhotic rats compared to control group probably due to constitutive nitric oxide synthase induction or inducible nitric oxide synthase inhibition."	3.79	Enhanced anti-ulcer effect of pioglitazone on gastric ulcers in cirrhotic rats: the role of nitric oxide and IL-1β. ( Amirghofran, Z; Dehpour, AR; Heidari, R; Moezi, L; Monabati, A; Nekooeian, AA, 2013)
" Liraglutide leading to improve not only glycaemic control but also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients."	3.78	The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. ( Isogawa, A; Iwamoto, M; Koike, K; Ohki, T; Ohsugi, M; Omata, M; Tagawa, K; Toda, N; Yoshida, H, 2012)
"Nonalcoholic steatohepatitis (NASH) is a leading cause of chronic liver disease for which there is limited therapy available."	2.73	Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. ( Aithal, GP; Austin, AS; Freeman, JG; Kaye, PV; Lawson, A; Morgan, L; Ryder, SD; Spendlove, I; Thomas, JA; Webber, J, 2008)
"NAFLD is found in up to 80% of people with obesity and over 60% of patients with diabetes."	2.72	Non-alcoholic fatty liver disease: Current therapeutic options. ( Majumdar, A; Tsochatzis, EA; Verbeek, J, 2021)
"However, most patients with NAFLD/NASH will die from a vascular cause."	2.72	Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. ( Atkin, SL; De Vincentis, A; Jamialahmadi, T; Mahjoubin-Tehran, M; Mantzoros, CS; Mikhailidis, DP; Sahebkar, A, 2021)
"Non-alcoholic fatty liver disease (NAFLD) exists as a spectrum ranging from simple steatosis to histologically defined hepatocyte injury and inflammatory changes that define steatohepatitis (NASH), and increase risk for fibrosis."	2.72	Zonation in NASH - A key paradigm for understanding pathophysiology and clinical outcomes. ( Pajvani, UB; Salomao, MA; Steinman, JB, 2021)
"Significant weight loss can improve NAFLD and nonalcoholic steatohepatitis (NASH)."	2.61	Nonalcoholic Fatty Liver Disease and Obesity Treatment. ( Brunner, KT; Henneberg, CJ; Long, MT; Wilechansky, RM, 2019)
"Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western industrialised countries."	2.61	Diagnosis and management of non-alcoholic fatty liver disease. ( Byrne, CD; Jennison, E; Patel, J; Scorletti, E, 2019)
"It also provides an overview of NAFLD agents currently under development."	2.55	Current and future pharmacologic treatment of nonalcoholic steatohepatitis. ( Banini, BA; Sanyal, AJ, 2017)
"NASH, the more aggressive form of NAFLD, may progress to cirrhosis and hepatocellular carcinoma."	2.55	Therapies in non-alcoholic steatohepatitis (NASH). ( Oseini, AM; Sanyal, AJ, 2017)
"When pioglitazone (n = 137) was analysed alone, the improvement in fibrosis with pioglitazone (n = 137) vs."	2.48	Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. ( Boettcher, E; Csako, G; Loomba, R; Pucino, F; Wesley, R, 2012)
" Long term administration of PPARgamma activator pioglitazone ameliorated the activity of NASH."	2.43	[PPAR and NASH]. ( Aoyama, T; Tanaka, N, 2006)
"At EOS, subjects with type 2 diabetes treated with triple therapy had less hepatic steatosis and fibrosis versus conventional therapy; the severity of hepatic steatosis and fibrosis were both strongly and inversely correlated with insulin resistance; and changes in liver fibrosis scores (APRI, NFS, Fibrosis-4, and AST/ALT ratio) have limited value in predicting response to therapy."	1.72	Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). ( Abdelgani, S; Abdul-Ghani, M; Adams, J; Alatrach, M; Alkhouri, N; Cersosimo, E; Clarke, GD; DeFronzo, RA; Gastaldelli, A; Lavynenko, O; Li, J; Puckett, C; Triplitt, C; Vasquez, JA, 2022)
"Associations between HRQoL and NAFLD disease activity score in the secondary analysis were of similar magnitude."	1.72	Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient-reported quality of life. ( Aveyard, P; Cobbold, JF; Heath, L; Koutoukidis, DA; Tomlinson, JW, 2022)
" Our findings demonstrated that chronic administration of PIO could not reverse the electrophysiological changes in the CA1 pyramidal neurons of the hippocampus in BDL rats but could improve the hepatic dysfunction."	1.72	Peroxisome proliferator-activated receptor-γ doesn't modify altered electrophysiological properties of the CA1 pyramidal neurons in a rat model of hepatic cirrhosis. ( Aghaei, I; Nazari, A; Pooladvand, V; Razavinasab, M; Shabani, M; Tahamtan, M, 2022)
"Treatment with bezafibrate or pioglitazone decreased the α-SMA expression."	1.62	Antifibrotic effects of bezafibrate and pioglitazone against thioacetamide-induced liver fibrosis in albino rats. ( Abdelrahman, AM; El-Tahawy, NF; Ibrahim, SA; Mohamed, MZ, 2021)
"In patient with NAFLD, interpretation of LSM in association with CAP scores may provide helpful information sparing unnecessary liver biopsy."	1.51	Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis. ( Lee, HW; Lee, JI; Lee, KS, 2019)
"Pioglitazone is an effective agent for chemoprevention in rodents and could be repurposed as a multi-targeted drug for delaying liver fibrosis and hepatocarcinogenesis."	1.51	Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. ( Arora, G; Baumert, TF; Erstad, DJ; Fuchs, BC; Ghoshal, S; Hoshida, Y; Lanuti, M; Li, S; Masia, R; Sojoodi, M; Tanabe, KK, 2019)
"Transplantation of mesenchymal stem cells (MSCs) in combination with pioglitazone, an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), can reduce liver fibrosis in models of liver injury."	1.43	Repeated Intraportal Injection of Mesenchymal Stem Cells in Combination with Pioglitazone in Patients with Compensated Cirrhosis: A Clinical Report of Two Cases. ( Aghdami, N; Akhlaghpoor, S; Ashrafi, M; Azimian, V; Baharvand, H; Hosseini, SE; Jarughi, N; Malekzadeh, R; Mardpour, S; Mohamadnejad, M; Moossavi, S; Nikfam, S; Vosough, M, 2016)
"Ipragliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor that increases urinary glucose excretion by inhibiting renal glucose reabsorption and thereby causes a subsequent antihyperglycemic effect."	1.42	Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. ( Hayashizaki-Someya, Y; Koide, K; Kurosaki, E; Mitori, H; Takakura, S; Takasu, T; Yamazaki, S, 2015)
"NASH, however, may progress to liver cirrhosis with risk of liver cancer."	1.38	[Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis]. ( Grønbæk, H; Heebøll, S; Kazankov, K; Poulsen, MK; Vilstrup, H, 2012)
"Nonalcoholic steatohepatitis (NASH) is the commonest liver disease in developed countries."	1.38	Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis. ( Craig, JC; George, J; Mahady, SE; Wong, G, 2012)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	8 (16.33)	29.6817
2010's	26 (53.06)	24.3611
2020's	15 (30.61)	2.80

Trial	Phase	Enrollment	Study Type	Start Date	Status
Calisthenics Versus High-intensity Interval Exercises on Health-related Outcomes in Patients With Non-alcoholic Fatty Liver[NCT06032650]		60 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
Effect of Low-Dose Pioglitazone in Patients With Nonalcoholic Steatohepatitis (NASH)[NCT04501406]	Phase 2	166 participants (Anticipated)	Interventional	2020-12-15	Recruiting
The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study[NCT03222206]	Phase 4	34 participants (Actual)	Interventional	2017-11-08	Completed
Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian Multicenter National Study[NCT04081571]		1,080 participants (Anticipated)	Observational	2019-04-01	Recruiting
A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis[NCT01950884]	Phase 4	45 participants (Anticipated)	Interventional	2013-10-31	Enrolling by invitation
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)[NCT00227110]	Phase 4	55 participants (Actual)	Interventional	2002-10-31	Completed
Low Glycemic Index Dietary Intervention Program in Nonalcoholic Fatty Liver Disease - A Randomized Controlled Trial[NCT00868933]		159 participants (Actual)	Interventional	2009-02-28	Completed
A Randomized,Placebo-controlled,Double-blind Trial of Phyllanthus Urinaria (Hepaguard®) in Adults With Nonalcoholic Steatohepatitis[NCT01210989]		60 participants (Actual)	Interventional	2010-05-31	Completed
Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease[NCT03459079]	Phase 2	54 participants (Anticipated)	Interventional	2018-08-14	Recruiting
Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial[NCT03198572]	Phase 4	120 participants (Anticipated)	Interventional	2017-08-16	Recruiting
[NCT00870012]		20 participants (Actual)	Interventional	2009-02-28	Completed
Comparative Clinical Study to Evaluate the Possible Beneficial Effect of Empagliflozin Versus Pioglitazone on Non-diabetic Patients With Non-Alcoholic Steatohepatitis[NCT05605158]	Phase 3	56 participants (Anticipated)	Interventional	2022-11-30	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Non-alcoholic fatty liver disease: Current therapeutic options. Current opinion in pharmacology, 2021, Volume: 61 Topics: Exercise; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone	2021
Current and new pharmacotherapy options for non-alcoholic steatohepatitis. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:8 Topics: Chenodeoxycholic Acid; Clinical Trials as Topic; Fibroblast Growth Factors; Glucagon-Like Peptides;	2020
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Molecular metabolism, 2021, Volume: 50 Topics: Biopsy; Disease Progression; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Di	2021
Efficacy and safety of drugs for nonalcoholic steatohepatitis. Journal of digestive diseases, 2021, Volume: 22, Issue:2 Topics: Diabetes Mellitus, Type 2; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Pharmaceutica	2021
Zonation in NASH - A key paradigm for understanding pathophysiology and clinical outcomes. Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:11 Topics: Hepatocytes; Humans; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Pioglitazone	2021
Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Alimentary pharmacology & therapeutics, 2021, Volume: 54, Issue:7 Topics: Biopsy; Humans; Liver Cirrhosis; Network Meta-Analysis; Non-alcoholic Fatty Liver Disease; Pioglitaz	2021
Current and future pharmacologic treatment of nonalcoholic steatohepatitis. Current opinion in gastroenterology, 2017, Volume: 33, Issue:3 Topics: Gastrointestinal Microbiome; Humans; Hypoglycemic Agents; Inflammation; Liver Cirrhosis; Liver Neopl	2017
Nonalcoholic Fatty Liver Disease and Obesity Treatment. Current obesity reports, 2019, Volume: 8, Issue:3 Topics: Bariatric Surgery; Body Weight; Diet; Exercise; Glucagon-Like Peptide 1; Humans; Inflammation; Insul	2019
Diagnosis and management of non-alcoholic fatty liver disease. Postgraduate medical journal, 2019, Volume: 95, Issue:1124 Topics: Antioxidants; Diabetes Mellitus, Type 2; Disease Management; Elasticity Imaging Techniques; Exercise	2019
The therapeutic landscape of non-alcoholic steatohepatitis. Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:5 Topics: Antioxidants; Chalcones; Chenodeoxycholic Acid; Disease Progression; Humans; Hypoglycemic Agents; In	2017
Therapies in non-alcoholic steatohepatitis (NASH). Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37 Suppl 1 Topics: Carcinoma, Hepatocellular; Diet; Disease Progression; Exercise; Fibrosis; Humans; Hypoglycemic Agent	2017
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:1 Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type	2009
Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Alimentary pharmacology & therapeutics, 2012, Volume: 35, Issue:1 Topics: Fatty Liver; Humans; Hypoglycemic Agents; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease;	2012
[PPAR and NASH]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:6 Topics: Acyl-CoA Oxidase; Animals; Cytokines; Fatty Liver; Gene Deletion; Humans; Inflammation Mediators; In	2006

Article	Year
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease. Journal of hepatology, 2023, Volume: 78, Issue:4 Topics: Biopsy; Fibrosis; Humans; Inflammation; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; P	2023
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease. Journal of hepatology, 2023, Volume: 78, Issue:4 Topics: Biopsy; Fibrosis; Humans; Inflammation; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; P	2023
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease. Journal of hepatology, 2023, Volume: 78, Issue:4 Topics: Biopsy; Fibrosis; Humans; Inflammation; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; P	2023
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease. Journal of hepatology, 2023, Volume: 78, Issue:4 Topics: Biopsy; Fibrosis; Humans; Inflammation; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; P	2023
Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. Journal of hepatology, 2020, Volume: 72, Issue:3 Topics: Adult; Biomarkers; Biopsy; Female; Humans; Hypoglycemic Agents; Inflammation; Liver; Liver Cirrhosis	2020
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology, 2008, Volume: 135, Issue:4 Topics: Adipokines; Adult; Aged; Alkaline Phosphatase; Fatty Liver; Female; Humans; Hypoglycemic Agents; Ins	2008
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology, 2008, Volume: 135, Issue:4 Topics: Adipokines; Adult; Aged; Alkaline Phosphatase; Fatty Liver; Female; Humans; Hypoglycemic Agents; Ins	2008
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology, 2008, Volume: 135, Issue:4 Topics: Adipokines; Adult; Aged; Alkaline Phosphatase; Fatty Liver; Female; Humans; Hypoglycemic Agents; Ins	2008
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology, 2008, Volume: 135, Issue:4 Topics: Adipokines; Adult; Aged; Alkaline Phosphatase; Fatty Liver; Female; Humans; Hypoglycemic Agents; Ins	2008
Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:2 Topics: Adult; Antiviral Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Stu	2012
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Blood Glucose; Caloric Restriction; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Bli	2006

Article	Year
Pioglitazone Ameliorates Acute Endotoxemia-Induced Acute on Chronic Renal Dysfunction in Cirrhotic Ascitic Rats. Cells, 2021, 11-05, Volume: 10, Issue:11 Topics: Acute Disease; Alanine Transaminase; Animals; Ascites; Bile Ducts; Bilirubin; Blood Vessels; Chronic	2021
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:5 Topics: Diabetes Mellitus, Type 2; Exenatide; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty	2022
Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient-reported quality of life. Hepatology communications, 2022, Volume: 6, Issue:10 Topics: Fibrosis; Humans; Ligands; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Patient Reported Outc	2022
Peroxisome proliferator-activated receptor-γ doesn't modify altered electrophysiological properties of the CA1 pyramidal neurons in a rat model of hepatic cirrhosis. Metabolic brain disease, 2022, Volume: 37, Issue:8 Topics: Animals; Bile Ducts; Disease Models, Animal; Ligation; Liver Cirrhosis; Male; Pioglitazone; PPAR gam	2022
Validation of a diet-induced Macaca fascicularis model of non-alcoholic steatohepatitis with dietary and pioglitazone interventions. Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:4 Topics: Animals; Diet, High-Fat; Disease Models, Animal; Liver; Liver Cirrhosis; Macaca fascicularis; Non-al	2023
A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF-β signaling in hepatic stellate cells. Scientific reports, 2023, 11-03, Volume: 13, Issue:1 Topics: Animals; Diet, High-Fat; Fibrosis; Gastrointestinal Microbiome; Hepatic Stellate Cells; Humans; Lino	2023
Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis. World journal of gastroenterology, 2019, Sep-07, Volume: 25, Issue:33 Topics: Adult; Biopsy; Disease Progression; Elasticity Imaging Techniques; Female; Follow-Up Studies; Humans	2019
Antifibrotic effects of bezafibrate and pioglitazone against thioacetamide-induced liver fibrosis in albino rats. Canadian journal of physiology and pharmacology, 2021, Volume: 99, Issue:3 Topics: Actins; Animals; Bezafibrate; Hepatic Stellate Cells; Liver; Liver Cirrhosis; Liver Function Tests;	2021
Pioglitazone decrease intrapulmonary shunt in biliary cirrhotic rats with hepatopulmonary syndrome. Journal of the Chinese Medical Association : JCMA, 2017, Volume: 80, Issue:11 Topics: Animals; Hepatopulmonary Syndrome; Liver Cirrhosis; Pioglitazone; Rats; Thiazolidinediones	2017
The effects of pioglitazone in cirrhotic rats with hepatopulmonary syndrome. Journal of the Chinese Medical Association : JCMA, 2017, Volume: 80, Issue:11 Topics: Angiogenesis Inhibitors; Animals; Endothelin-1; Hepatopulmonary Syndrome; Liver Cirrhosis; Male; Nit	2017
Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis. Biochemical and biophysical research communications, 2018, 02-26, Volume: 497, Issue:1 Topics: Animals; Dose-Response Relationship, Drug; Drug Combinations; Hypoglycemic Agents; Liver; Liver Cirr	2018
Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2019, Volume: 23, Issue:1 Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Choline; Diet, High-	2019
Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand. PharmacoEconomics, 2019, Volume: 37, Issue:2 Topics: Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Hypoglycemic Agents; Liver Cirrhosis; Live	2019
Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. Hepatology (Baltimore, Md.), 2019, Volume: 70, Issue:2 Topics: Adult; Biopsy; Chenodeoxycholic Acid; Female; Humans; Hypoglycemic Agents; Liver Cirrhosis; Male; Mi	2019
Enhanced anti-ulcer effect of pioglitazone on gastric ulcers in cirrhotic rats: the role of nitric oxide and IL-1β. Pharmacological reports : PR, 2013, Volume: 65, Issue:1 Topics: Animals; Anti-Ulcer Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Interleukin-1b	2013
Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. European journal of pharmacology, 2015, May-05, Volume: 754 Topics: Amino Acids; Animals; Choline Deficiency; Food, Formulated; Glucosides; Hydroxyproline; Hypoglycemic	2015
Effect of pioglitazone, quercetin, and hydroxy citric acid on vascular endothelial growth factor messenger RNA (VEGF mRNA) expression in experimentally induced nonalcoholic steatohepatitis (NASH). Turkish journal of medical sciences, 2015, Volume: 45, Issue:3 Topics: Analysis of Variance; Animals; Antioxidants; Calcium Chelating Agents; Citric Acid; Disease Models,	2015
TLR4‑dependent signaling pathway modulation: A novel mechanism by which pioglitazone protects against nutritional fibrotic steatohepatitis in mice. Molecular medicine reports, 2016, Volume: 13, Issue:3 Topics: Animals; Chemokines; Choline; Diet; Down-Regulation; Fibrosis; Inflammation; Liver; Liver Cirrhosis;	2016
Repeated Intraportal Injection of Mesenchymal Stem Cells in Combination with Pioglitazone in Patients with Compensated Cirrhosis: A Clinical Report of Two Cases. Archives of Iranian medicine, 2016, Volume: 19, Issue:2 Topics: Adult; Female; Humans; Hypoglycemic Agents; Infusions, Intravenous; Liver Cirrhosis; Male; Mesenchym	2016
Solanum nigrum Protects against Hepatic Fibrosis via Suppression of Hyperglycemia in High-Fat/Ethanol Diet-Induced Rats. Molecules (Basel, Switzerland), 2016, Feb-25, Volume: 21, Issue:3 Topics: Animals; Diet, High-Fat; Ethanol; Gene Expression Regulation; Glycation End Products, Advanced; Hepa	2016
The Role of Pioglitazone in the Management of Nonalcoholic Steatohepatitis: Are We There Yet? JAMA internal medicine, 2017, 05-01, Volume: 177, Issue:5 Topics: Humans; Hypoglycemic Agents; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiaz	2017
PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. American journal of physiology. Renal physiology, 2011, Volume: 300, Issue:2 Topics: Animals; Blood Urea Nitrogen; Cell Proliferation; Disease Models, Animal; Disease Progression; Femal	2011
[Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis]. Ugeskrift for laeger, 2012, Feb-20, Volume: 174, Issue:8 Topics: Fatty Liver; Humans; Hypoglycemic Agents; Liver Cirrhosis; Liver Neoplasms; Pioglitazone; Prognosis;	2012
Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis. Hepatology (Baltimore, Md.), 2012, Volume: 56, Issue:6 Topics: Combined Modality Therapy; Cost-Benefit Analysis; Fatty Liver; Humans; Hypoglycemic Agents; Life Sty	2012
The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. TheScientificWorldJournal, 2012, Volume: 2012 Topics: Adult; Alanine Transaminase; Blood Glucose; Body Weight; Comorbidity; Diabetes Mellitus, Type 2; Dru	2012
Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway. Clinical and experimental pharmacology & physiology, 2012, Volume: 39, Issue:12 Topics: Animals; Body Weight; Cyclic AMP-Dependent Protein Kinases; Diet, High-Fat; Fatty Liver; Hypoglycemi	2012
Effects of PPARg agonist pioglitazone on rat hepatic fibrosis. World journal of gastroenterology, 2004, Apr-01, Volume: 10, Issue:7 Topics: Animals; Hydroxyproline; Liver; Liver Cirrhosis; Male; Pioglitazone; Rats; Rats, Sprague-Dawley; Rec	2004
Pioglitazone in nonalcoholic steatohepatitis. The New England journal of medicine, 2007, Mar-08, Volume: 356, Issue:10 Topics: Animals; Anti-Inflammatory Agents; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Liver; H	2007
Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochemical and biophysical research communications, 2002, Feb-15, Volume: 291, Issue:1 Topics: Actins; Animals; Carbon Tetrachloride; Cells, Cultured; Collagen Type I; Dose-Response Relationship,	2002
Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology, 2002, Volume: 122, Issue:7 Topics: Animals; Benzhydryl Compounds; Bile Ducts; Carbon Tetrachloride; Cell Division; Cells, Cultured; Col	2002

pioglitazone and Cirrhosis, Liver

Research Excerpts

Research

Studies (49)

Authors

Clinical Trials (12)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Majumdar, A	1
Verbeek, J	1
Tsochatzis, EA	1
Liu, SY	1
Huang, CC	1
Huang, SF	1
Liao, TL	1
Kuo, NR	1
Yang, YY	2
Li, TH	1
Liu, CW	1
Hou, MC	1
Lin, HC	2
Lavynenko, O	1
Abdul-Ghani, M	1
Alatrach, M	1
Puckett, C	1
Adams, J	1
Abdelgani, S	1
Alkhouri, N	1
Triplitt, C	1
Clarke, GD	1
Vasquez, JA	1
Li, J	1
Cersosimo, E	1
Gastaldelli, A	2
DeFronzo, RA	1
Heath, L	1
Aveyard, P	1
Tomlinson, JW	1
Cobbold, JF	1
Koutoukidis, DA	1
Tahamtan, M	1
Aghaei, I	1
Shabani, M	1
Nazari, A	1
Pooladvand, V	1
Razavinasab, M	1
Sanyal, AJ	5
Williams, SA	2
Lavine, JE	2
Neuschwander-Tetri, BA	3
Alexander, L	2
Ostroff, R	2
Biegel, H	2
Kowdley, KV	2
Chalasani, N	3
Dasarathy, S	2
Diehl, AM	2
Loomba, R	4
Hameed, B	2
Behling, C	2
Kleiner, DE	3
Karpen, SJ	2
Williams, J	2
Jia, Y	2
Yates, KP	2
Tonascia, J	2
Camacho, RC	1
Polidori, D	1
Chen, T	1
Chen, B	1
Hsu, HH	1
Gao, B	1
Marella, M	1
Lubomirski, M	1
Beavers, T	1
Cabrera, J	1
Wong, P	1
Nawrocki, AR	1
Kasahara, N	1
Imi, Y	1
Amano, R	1
Shinohara, M	1
Okada, K	1
Hosokawa, Y	1
Imamori, M	1
Tomimoto, C	1
Kunisawa, J	1
Kishino, S	1
Ogawa, J	1
Ogawa, W	1
Hosooka, T	1
Lee, JI	1
Lee, HW	1
Lee, KS	1
Bril, F	1
Barb, D	1
Lomonaco, R	1
Lai, J	1
Cusi, K	2
Sumida, Y	1
Yoneda, M	2
Ogawa, Y	1
Okanoue, T	1
Nakajima, A	1
Mahjoubin-Tehran, M	1
De Vincentis, A	1
Mikhailidis, DP	1
Atkin, SL	1
Mantzoros, CS	1
Jamialahmadi, T	1
Sahebkar, A	1
Ibrahim, SA	1
Mohamed, MZ	1
El-Tahawy, NF	1
Abdelrahman, AM	1
Shen, B	1
Lu, LG	1
Steinman, JB	1
Salomao, MA	1
Pajvani, UB	1
Majzoub, AM	1
Nayfeh, T	1
Barnard, A	1
Munaganuru, N	1
Dave, S	1
Singh, S	1
Murad, MH	1
Banini, BA	1
Tsai, HC	1
Cheng, TY	1
Lee, WS	1
Huang, HC	1
Lee, FY	1
Chang, CC	1
Lee, SD	1
Amano, Y	1
Tsuchiya, S	1
Imai, M	1
Tohyama, K	1
Matsukawa, J	1
Isono, O	1
Yasuno, H	1
Enya, K	1
Koumura, E	1
Nagabukuro, H	1
Li, S	1
Ghoshal, S	1
Sojoodi, M	1
Arora, G	1
Masia, R	1
Erstad, DJ	1
Lanuti, M	1
Hoshida, Y	1
Baumert, TF	1
Tanabe, KK	1
Fuchs, BC	1
Chongmelaxme, B	1
Phisalprapa, P	1
Sawangjit, R	1
Dilokthornsakul, P	1
Chaiyakunapruk, N	1
Brunt, EM	1
Wilson, LA	1
Brunner, KT	1
Henneberg, CJ	1
Wilechansky, RM	1
Long, MT	1
Jennison, E	1
Patel, J	1
Scorletti, E	1
Byrne, CD	1
Moezi, L	1
Heidari, R	1
Amirghofran, Z	1
Nekooeian, AA	1
Monabati, A	1
Dehpour, AR	1
Hayashizaki-Someya, Y	1
Kurosaki, E	1
Takasu, T	1
Mitori, H	1
Yamazaki, S	1
Koide, K	1
Takakura, S	1
Surapaneni, KM	1
Vishnu Priya, V	1
Mallika, J	1
Du, J	1
Niu, X	1
Wang, R	1
Zhao, S	1
Kong, L	1
Zhang, Y	1
Nan, Y	1
Vosough, M	1
Moossavi, S	1
Mardpour, S	1
Akhlaghpoor, S	1
Azimian, V	1
Jarughi, N	1
Hosseini, SE	1
Ashrafi, M	1
Nikfam, S	1
Aghdami, N	1
Malekzadeh, R	1
Mohamadnejad, M	1
Baharvand, H	1
Tai, CJ	2
Choong, CY	1
Shi, YC	1
Lin, YC	1
Wang, CW	1
Lee, BH	1
Perazzo, H	1
Dufour, JF	1
Oseini, AM	1
Yee, HF	1
Aithal, GP	1
Thomas, JA	1
Kaye, PV	1
Lawson, A	1
Ryder, SD	1
Spendlove, I	1
Austin, AS	1
Freeman, JG	1
Morgan, L	1
Webber, J	1
Vuppalanchi, R	1
Yoshihara, D	1
Kurahashi, H	1
Morita, M	1
Kugita, M	1
Hiki, Y	1
Aukema, HM	1
Yamaguchi, T	1
Calvet, JP	1
Wallace, DP	1
Nagao, S	1
Boettcher, E	1
Csako, G	1
Pucino, F	1
Wesley, R	1
Harrison, SA	2
Hamzeh, FM	1
Han, J	1
Pandya, PK	1
Sheikh, MY	1
Vierling, JM	1
Heebøll, S	1
Kazankov, K	1
Poulsen, MK	1
Vilstrup, H	1
Grønbæk, H	1
Mahady, SE	1
Wong, G	1
Craig, JC	1
George, J	1
Ohki, T	1
Isogawa, A	1
Iwamoto, M	1
Ohsugi, M	1
Yoshida, H	1
Toda, N	1
Tagawa, K	1
Omata, M	1
Koike, K	1
Zhang, W	1
Wu, R	1
Zhang, F	1
Xu, Y	1
Liu, B	1
Yang, Y	1
Zhou, H	1
Wang, L	1
Wan, K	1
Xiao, X	1
Zhang, X	1
Yuan, GJ	1
Zhang, ML	1
Gong, ZJ	1
Tanaka, N	1
Aoyama, T	1
Belfort, R	1
Brown, K	1
Darland, C	1
Finch, J	1
Hardies, J	1
Balas, B	1
Tio, F	1
Pulcini, J	1
Berria, R	1
Ma, JZ	1
Dwivedi, S	1
Havranek, R	1
Fincke, C	1
DeFronzo, R	1
Bannayan, GA	1
Schenker, S	1
Ota, T	1
Takamura, T	1
Kaneko, S	1
Kon, K	1
Ikejima, K	1
Hirose, M	1
Yoshikawa, M	1
Enomoto, N	1
Kitamura, T	1
Takei, Y	1
Sato, N	1
Galli, A	1
Crabb, DW	1
Ceni, E	1
Salzano, R	1
Mello, T	1
Svegliati-Baroni, G	1
Ridolfi, F	1
Trozzi, L	1
Surrenti, C	1
Casini, A	1